Managing myelodysplastic symptoms in elderly patients

References

• RollisonDEHowladerNSmithMTEpidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States 2001–2004, using data from the NAACCR and SEER programsBlood2008112455218443215
   PubMed Web of Science ®Google Scholar
• GuralnikJMEisenstaedtRSFerrucciLPrevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemiaBlood20041042263226815238427
   PubMed Web of Science ®Google Scholar
• HoweRBPorwit-MacDonaldAWanatRThe WHO classification of MDS does make a differenceBlood20041033265327014684416
   PubMed Web of Science ®Google Scholar
• AlessandrinoEPAmadoriSCazzolaMMyelodysplastic syndromes: recent advancesHaematologica2001861124115711694400
   PubMed Web of Science ®Google Scholar
• Hellström-LindbergEWillmanCBarrettJSaunthararajahYAchievements in understanding and treatment of myelodysplastic syndromesAmerican Society of Hematology Education Program Book200011013211701538
   PubMedGoogle Scholar
• De WitteTSuciuSVerhoefGIntensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDSBlood2001982326233111588026
   PubMed Web of Science ®Google Scholar
• GreenbergPCoxCLeBeauMMInternational scoring system for evaluating prognosis in myelodysplastic syndromesBlood199789207920889058730
   PubMed Web of Science ®Google Scholar
• ChesonBDBennettJMKantarjianHReport of an international working group to standardize response criteria for myelodysplastic syndromesBlood2000963671367411090046
   PubMed Web of Science ®Google Scholar
• AdèsLBoehrerSPrebetTEfficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 studyBlood20091133947395218987358
   PubMed Web of Science ®Google Scholar
• MalcovatiLGermingUKuendgenATime-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromesJ Clin Oncol2007253503351017687155
   PubMed Web of Science ®Google Scholar
• GermingUHildebrandtBPfeilstöckerMRefinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)Leukemia2005192223223116193087
   PubMed Web of Science ®Google Scholar
• Garcia-ManeroGShanJFaderlSA prognostic score for patients with lower risk myelodysplastic syndromeLeukemia20082253854318079733
   PubMed Web of Science ®Google Scholar
• KantarjianHO’BrienSRavandiFProposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemCancer20081131351136118618511
   PubMed Web of Science ®Google Scholar
• BullingerMHasfordJEvaluating quality-of-life measures for clinical trials in GermanyControl Clin Trials19911291S105S1663863
   PubMedGoogle Scholar
• RichTInnominatoPFBoernerJElevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancerClin Cancer Res2005111757176415755997
   PubMed Web of Science ®Google Scholar
• MeyersCAAlbitarMEsteyECognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndromeCancer200510478879315973668
   PubMed Web of Science ®Google Scholar
• HsuHCLeeYMTsaiWHCirculating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndromeOncology200263646912187073
   PubMed Web of Science ®Google Scholar
• TefferiAIron chelation therapy for myelodysplastic syndrome: If and whenMayo Clin Proc20068119719816471074
   PubMed Web of Science ®Google Scholar
• ChavesPHFunctional outcomes of anemia in older adultsSemin Hematol20084525526018809096
   PubMed Web of Science ®Google Scholar
• FriedLPTangenCMWalstonJFrailty in older adults: evidence for a phenotypeJ Gerontol A Biol Sci Med Sci200156M146M15611253156
   PubMed Web of Science ®Google Scholar
• ZakaiNAKatzRHirschCA prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health StudyArch Intern Med20051652214222016246985
   PubMed Web of Science ®Google Scholar
• ChavesPHXueQLGuralnikJMWhat constitutes normal hemoglobin concentration in community-dwelling disabled older women?J Am Geriatr Soc2004521811181615507056
   PubMed Web of Science ®Google Scholar
• BowenDCulliganDJowittSGuidelines for the diagnosis and therapy of adult myelodysplastic syndromesBr J Haematol200312018720012542475
   PubMed Web of Science ®Google Scholar
• JansenAJEssink-BotMLBeckersEAQuality of life measurement in patients with transfusion-dependent myelodysplastic syndromesBr J Haematol200312127027412694248
   PubMed Web of Science ®Google Scholar
• ListAFBaerMRSteensmaDDeferasirox (ICL670; Exjade) reduces serum ferritin (SF) and labile plasma iron (LPI) in patients with myelodysplastic syndrome [abstract 1470]Blood (ASH Annual Meeting Abstracts)2007110440a
   Web of Science ®Google Scholar
• RoseCBrechignacSVassiliefDPositive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients; a prospective analysis by the GFM [abstract 249]Blood (ASH Annual Meeting Abstracts)200711080a
   Web of Science ®Google Scholar
• Hellström-LindbergEEfficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studiesBr J Haematol19958967717833279
   PubMed Web of Science ®Google Scholar
• A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic SyndromesBr J Haematol1998103107010749886322
   PubMed Web of Science ®Google Scholar
• Hellström-LindbergENegrinRSteinRErythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive modelBr J Haematol1997993443519375752
   PubMed Web of Science ®Google Scholar
• TerposEMougiouAKouraklisAProlonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patientsBr J Haematol200211817418012100145
   PubMed Web of Science ®Google Scholar
• GiraldoPNomdedeuBLoscertalesJDarbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromesCancer20061072807281617115424
   PubMed Web of Science ®Google Scholar
• GolshayanARJinTMaciejewskiJEfficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromesBr J Haematol200713712513217391492
   PubMed Web of Science ®Google Scholar
• NCCN practice guidelines for the myelodysplastic syndromesNational Comprehensive Cancer NetworkOncology199812538010028503
   PubMedGoogle Scholar
• TiuRVSekeresMAThe role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromesExpert Opin Biol Ther200881021103018549331
   PubMed Web of Science ®Google Scholar
• GaliliNCernyJRazaACurrent treatment options: impact of cytogenetics on the course of myelodysplasiaCurr Treat Options Oncol2007811712817634837
   PubMedGoogle Scholar
• De WitteTZwaanFHermansJAllogeneic bone marrow transplantation for secondary leukemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG)Br J Haematol1990741511552180469
   PubMed Web of Science ®Google Scholar
• KuendgenAStruppCAivadoMMyelodysplastic syndromes in patients younger than age 50J Clin Oncol2006245358536517088566
   PubMed Web of Science ®Google Scholar
• SierraJPérezWSRozmanCBone marrow transplantation from HLA-identical sibvling as treatment for myelodysplasiaBlood20021001997200412200358
   PubMed Web of Science ®Google Scholar
• WarlickEDCiocADeforTAllogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burdenBiol Blood Marrow Transplant200915303819135940
   PubMed Web of Science ®Google Scholar
• AppelbaumFRAndersonJAllogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS scoreLeukemia199812Suppl 1S25S299777891
   PubMed Web of Science ®Google Scholar
• CutlerCSLeeSJGreenbergPA decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcomeBlood200410457958515039286
   PubMed Web of Science ®Google Scholar
• BaccaraniMTuraSDifferentiation of myeloid leukaemic cells: new possibilities for therapyBr J Haematol197942485487289407
   PubMed Web of Science ®Google Scholar
• WischJSGriffinJDKufeDWResponse of preleukemic syndromes to continuous infusion of low-dose cytarabineN Engl J Med1983309159916026646185
   PubMed Web of Science ®Google Scholar
• MillerKBKimKMorrisonFSThe evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup studyAnn Hematol1992651621681420504
   PubMed Web of Science ®Google Scholar
• ClarkREIsmailSAJacobsAA randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndromeBr J Haematol19876677833297129
   PubMed Web of Science ®Google Scholar
• GarewalHGreenbergPListAN-(4-hydroxyphenyl) retinamide [4-HPR] therapy in myelodysplastic syndromes (MDS): possible disease acceleration by retinoidsBlood (ASH Annual Meeting Abstracts)198770228a
   Google Scholar
• ChesonBDThe myelodysplastic syndromes: current approaches to therapyAnn Intern Med19901129329412187393
   PubMed Web of Science ®Google Scholar
• SabaHIShamimFIsmailRAcute leukemic transformation in myelodysplastic syndrome. [abstract]Blood (ASH Annual Meeting Abstracts)199280459a
   Google Scholar
• Gafter-GviliAFraserAPaulMLeiboviciLMeta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patientsAnn Intern Med200514297999515968013
   PubMed Web of Science ®Google Scholar
• ListADewaldGBennettJLenalidomide in the myelodysplastic syndrome with chromosome 5q deletionN Engl J Med20063551456146517021321
   PubMed Web of Science ®Google Scholar
• RazaAReevesJAFeldmanEJPhase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qBlood2008111869317893227
   PubMed Web of Science ®Google Scholar
• SilvermanLRDemakosEPPetersonBLRandomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group BJ Clin Oncol2002202429244012011120
   PubMed Web of Science ®Google Scholar
• FenauxPSantiniVHellstrom-LindbergEEfficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyLancet Oncol20091022323219230772
   PubMed Web of Science ®Google Scholar
• KantarjianHIssaJPRosenfeldCSDecitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized studyCancer20061061794180316532500
   PubMed Web of Science ®Google Scholar
• MolldremJJCaplesMMavroudisDAntithymocyte globulin for patients with myelodysplastic syndromeBr J Haematol1997996997059401087
   PubMed Web of Science ®Google Scholar
• SorrorMLSandmaierBMStorerBEComorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantationJ Clin Oncol2007254246425417724349
   PubMed Web of Science ®Google Scholar
• SloandEMWuCOGreenbergPFactors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapyJ Clin Oncol2008262505251118413642
   PubMed Web of Science ®Google Scholar
• SaunthararajahYNakamuraRNamJMHLA-DR15 (DR2) is ovvererepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndromeBlood20021001570157412176872
   PubMed Web of Science ®Google Scholar